SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers

Francesca Rovida, Irene Cassaniti, Stefania Paolucci, Elena Percivalle, Antonella Sarasini, Antonio Piralla, Federica Giardina, Josè Camilla Sammartino, Alessandro Ferrari, Federica Bergami, Alba Muzzi, Viola Novelli, Alessandro Meloni, Sara Cutti, Anna Maria Grugnetti, Giuseppina Grugnetti, Claudia Rona, Marinella Daglio, Carlo Marena, Antonio Triarico, Daniele Lilleri () and Fausto Baldanti
Additional contact information
Francesca Rovida: Fondazione IRCCS Policlinico San Matteo
Irene Cassaniti: Fondazione IRCCS Policlinico San Matteo
Stefania Paolucci: Fondazione IRCCS Policlinico San Matteo
Elena Percivalle: Fondazione IRCCS Policlinico San Matteo
Antonella Sarasini: Fondazione IRCCS Policlinico San Matteo
Antonio Piralla: Fondazione IRCCS Policlinico San Matteo
Federica Giardina: Fondazione IRCCS Policlinico San Matteo
Josè Camilla Sammartino: Fondazione IRCCS Policlinico San Matteo
Alessandro Ferrari: Fondazione IRCCS Policlinico San Matteo
Federica Bergami: Fondazione IRCCS Policlinico San Matteo
Alba Muzzi: Fondazione IRCCS Policlinico San Matteo
Viola Novelli: Fondazione IRCCS Policlinico San Matteo
Alessandro Meloni: Fondazione IRCCS Policlinico San Matteo
Sara Cutti: Fondazione IRCCS Policlinico San Matteo
Anna Maria Grugnetti: Fondazione IRCCS Policlinico San Matteo
Giuseppina Grugnetti: Fondazione IRCCS Policlinico San Matteo
Claudia Rona: Fondazione IRCCS Policlinico San Matteo
Marinella Daglio: Fondazione IRCCS Policlinico San Matteo
Carlo Marena: Fondazione IRCCS Policlinico San Matteo
Antonio Triarico: Fondazione IRCCS Policlinico San Matteo
Daniele Lilleri: Fondazione IRCCS Policlinico San Matteo
Fausto Baldanti: Fondazione IRCCS Policlinico San Matteo

Nature Communications, 2021, vol. 12, issue 1, 1-7

Abstract: Abstract Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58–93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p = 0.01). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection.

Date: 2021
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-021-26154-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-26154-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-26154-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().